Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Trial Details

NCT ID

NCT06211790

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

• Anlotinib, Everolimus and Tislelizumab

Locations (sample)

• Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

• Patients who meet the following criteria are eligible to participate in the trial:
• Male or female aged 18 and ≤ 75;
• Histologically or cytologically confirmed unresectable or metastatic clear cell carcinoma of the kidney, which may contain sarcomatoid lesions;
• At least one measurable target lesion at the time of enrollment according to RECIST1.1(Response Evaluation Criteria In Solid Tumors) standards;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.